Product Description
Legend Biotech is developing a CD20 CAR-alpha betaT for NHL. (Sourced from: https://legendbiotech.com/research-development/pipeline/)
Mechanisms of Action: CAR-T,CD20
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Legend Biotech
Company Location: SOMERSET NJ 08873
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for CD20 CAR-T - Legend Biotech](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|